Key Stats for Novo Nordisk Stock
- Pre-Market Price change for Novo Nordisk stock Today: -4%
- $NVO Share Price as of Mar. 2: $38
- 52-Week High: $92
- $NVO Stock Price Target: $41
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock took another hit this week after Goldman Sachs downgraded the company from buy to neutral, slashing its price target from $63 to $41. Novo Nordisk stock is now trading at a 52-week low.
The downgrade follows disappointing Phase 3 trial results for CagriSema, Novo’s next-generation obesity drug, which was expected to be a major growth driver.
Last week, Novo Nordisk announced that CagriSema failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide after 84 weeks of treatment.
This was a significant setback, as investors had high expectations for the drug to compete effectively in the rapidly growing obesity treatment market.
Goldman analyst James Quigley slashed his CagriSema sales projections dramatically, from $11.8 billion to just $5 billion.
This cut led to reduced topline estimates of about 6% and operating profit estimates down roughly 10% across 2026 through 2030.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
What the Market Is Telling Us About Novo Nordisk Stock
Novo Nordisk stock has been hit hard, tumbling 21% last week and hitting a new 52-week low on Monday. The stock is now down drastically from its peak, reflecting serious investor concern about the company’s competitive position in the obesity drug market.
Goldman didn’t downgrade to sell because there are still some potential positives.
The recent launch of the Wegovy pill showed strong early uptake with about 50,000 weekly prescriptions, and Medicare coverage for obesity drugs starting mid-year could unlock significant volume growth.
Additionally, the readout of the ziltivekimab Phase 3 trial, expected in the second half of 2026, could provide another catalyst.
However, Quigley noted that Novo Nordisk stock has become a “show-me story,” meaning investors now want to see actual results before they’re willing to pay up for the shares.
With Eli Lilly appearing to take market share and Novo facing pricing headwinds, the path forward looks uncertain for now, despite the company’s strong legacy in diabetes and obesity treatments.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
